Trial Profile
A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abelacimab (Primary) ; Apixaban
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Sep 2018 Status changed from withdrawn prior to enrolment to not yet recruiting.
- 10 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.